Seite - (000409) - in Biomedical Chemistry: Current Trends and Developments

using interleukin-2. A review. Annals of Surgery, 208(2), 121-135. Roy, A., Singh, M. S., Upadhyay, P., et al. (2013). Nanoparticle mediated co-delivery of paclitaxel and a tlr-4 agonist results in tumor regression and enhanced immune response in the tumor microenvironment of a mouse model. International Journal of Pharmaceutics, 445(1-2), 171- 180. Saad, M., Garbuzenko, O. B., Minko, T. (2008). Co-delivery of sirna and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine, 3(6), 761-776. Salonen, J., Kaukonen, A. M., Hirvonen, J., et al. (2008). Mesoporous silicon in drug delivery applications. Journal of Pharmaceutical Sciences, 97(2), 632-653. Sangha, R., Butts, C. (2007). L-blp25: A peptide vaccine strategy in non small cell lung cancer. Clinical Cancer Research, 13(15 Pt 2), s4652-4654. Sanna, V., Pala, N., Sechi, M. (2014). Targeted therapy using nanotechnology: Focus on cancer. International Journal of Nanomedicine, 9, 467-483. Santos, H. A., Bimbo, L. M., Herranz, B., et al. (2013a). Nanostructured porous silicon in preclinical imaging: Moving from bench to bedside. Journal of Materials Research, 28(02), 152-164. Santos, H. A., Mäkilä, E., Airaksinen, Anu J., et al. (2014). Porous silicon nanoparticles for nanomedicine: Preparation and biomedical applications. Nanomedicine, 9(4), 535-554. Santos, H. A., Peltonen, L., Limnell, T., et al. (2013). Mesoporous materials and nanocrystals for enhancing the dissolution behavior of poorly water-soluble drugs. Current Pharmaceutical Biotechnology, 14(10), 926-938. Sarparanta, M. P., Bimbo, L. M., Mäkilä, E. M., et al. (2012). The mucoadhesive and gastroretentive properties of hydrophobin-coated porous silicon nanoparticle oral drug delivery systems. Biomaterials, 33(11), 3353-3362. Satpathy, M., Zielinski, R., Lyakhov, I., et al. (2015). Optical imaging of ovarian cancer using her- 2 affibody conjugated nanoparticles. Methods in Molecular Biology, 1219, 171-185. Sawant, R. R., Torchilin, V. P. (2012). Challenges in development of targeted liposomal therapeutics. The AAPS Journal, 14(2), 303-315. Schmitt-Sody, M., Strieth, S., Krasnici, S., et al. (2003). Neovascular targeting therapy: Paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clinical Cancer Research, 9(6), 2335-2341. Scott, A. M., Wolchok, J. D., Old, L. J. (2012). Antibody therapy of cancer. Nature Reviews Cancer, 12(4), 278-287. Shahbazi, M.-A., Herranz, B., Santos, H. A. (2012). Nanostructured porous si-based nanoparticles for targeted drug delivery. Biomatter, 2(4), 296-312. Sharma, S., Mukkur, T. K., Benson, H. A., et al. (2009). Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. Journal of Pharmaceutical Sciences, 98(3), 812-843. Shi, C., Guo, X., Qu, Q., et al. (2014). Actively targeted delivery of anticancer drug to tumor cells by redox-responsive star-shaped micelles. Biomaterials, 35(30), 8711-8722. Shi, H., Huang, Y., Zhou, H., et al. (2007). Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood, 110(8), 2899-2906. Shi, J. J., Xiao, Z. Y., Kamaly, N., et al. (2011). Self-assembled targeted nanoparticles: Evolution of